6,603 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Haverford Financial Services Inc.

Haverford Financial Services Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,603 shares of the medical research company’s stock, valued at approximately $3,310,000.

A number of other institutional investors have also made changes to their positions in TMO. Legacy Wealth Managment LLC ID raised its stake in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares during the period. Kilter Group LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at approximately $25,000. Allied Private Wealth LLC purchased a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $26,000. High Note Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the period. Finally, Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on TMO shares. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Royal Bank Of Canada upped their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $71,191,194.75. This trade represents a 7.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 63,493 shares of company stock worth $37,657,681. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $629.02 on Monday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market capitalization of $232.58 billion, a PE ratio of 33.84, a price-to-earnings-growth ratio of 2.56 and a beta of 0.84. The business’s fifty day moving average price is $542.53 and its 200 day moving average price is $509.19.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the business earned $4.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.